This work is significant for Black breast cancer patients, who may require CLIA-certified genetic testing because it employs comprehensive sequencing to identify more than the three Ashkenazi Jewish founder variants in BRCA1 and BRCA2 assessed by some DTC genetic tests. Here, BRCA2 is linked to breast cancer.